Future Innovations in Treating Advanced Prostate Cancer

Pratik Desai, Juan A. Jiménez, Chinghai Kao, Thomas Gardner

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Many novel techniques for the treatment of prostate cancer are being aggressively investigated for two reasons: (1) prostate cancer is prevalent in the population, and (2) the current treatments for advanced prostate cancer are woefully inadequate. Antiangiogenesis has great potential as stand-alone therapy to transform prostate cancer into a chronic disease or, in combination with the available therapies, to provide curative approaches with decreased treatment-related morbidities. Further understanding of the angiogenic cascade will reveal additional molecular targets and advancements in molecular delivery approaches, such as gene therapy, will lead to the development of safe and effective treatment strategies. There are many complex interactions between the immune system and prostate cancer. Although our understanding of these interactions is improving, further understanding will lead to novel treatment strategies. These include the idea that manipulation of cellular pathways, such as the work with growth factor receptors, can lead to tumor stabilization and eventually cytoreduction with continued cell turnover. The adjuvant use of immunotherapy for prostate cancer could also help increase efficacy of current oncologic treatments. This may be even more significant when used in conjuction with nomograms that may predict men who are at particularly high risk for failure of local treatment, and who would be better served with adjuvent immune therapy. The safety and efficacy of gene therapy for prostate cancer has been demonstrated through various preclinical and clinical trials, and potentially holds the greatest promise. In recent years, interest in this field has expanded and will continue to do so. Because it is conveniently administered through ultrasound-guided transrectal injection, it is also conceivable that gene therapy applied in an outpatient clinic may someday replace current therapy to treat early prostate cancer. As a therapy, it is the culmination of the work of many disciplines that will result in an elegant targeted, efficient, and versatile strategy against prostate cancer. It is conceivable that, in the near future, any of these experimental modalities will be developed to replace hormone ablation therapy which causes unpleasant side effects, decreases the quality of life of the patient, and only temporarily controls the disease. Factors that limit the disseminated use of these advanced therapies as standards of care include time, funding, and fear from the general public; however, these should diminish as the number of successful clinical trials increase.

Original languageEnglish
Pages (from-to)247-272
Number of pages26
JournalUrologic Clinics of North America
Volume33
Issue number2
DOIs
StatePublished - May 2006

Fingerprint

Prostatic Neoplasms
Therapeutics
Genetic Therapy
Clinical Trials
Nomograms
Growth Factor Receptors
Standard of Care
Ambulatory Care Facilities
Treatment Failure
Immunotherapy
Fear
Immune System
Chronic Disease
Quality of Life
Hormones
Morbidity
Safety
Injections

ASJC Scopus subject areas

  • Urology

Cite this

Future Innovations in Treating Advanced Prostate Cancer. / Desai, Pratik; Jiménez, Juan A.; Kao, Chinghai; Gardner, Thomas.

In: Urologic Clinics of North America, Vol. 33, No. 2, 05.2006, p. 247-272.

Research output: Contribution to journalArticle

@article{0cdc82bb23664aa8bded95b8fbe1fef9,
title = "Future Innovations in Treating Advanced Prostate Cancer",
abstract = "Many novel techniques for the treatment of prostate cancer are being aggressively investigated for two reasons: (1) prostate cancer is prevalent in the population, and (2) the current treatments for advanced prostate cancer are woefully inadequate. Antiangiogenesis has great potential as stand-alone therapy to transform prostate cancer into a chronic disease or, in combination with the available therapies, to provide curative approaches with decreased treatment-related morbidities. Further understanding of the angiogenic cascade will reveal additional molecular targets and advancements in molecular delivery approaches, such as gene therapy, will lead to the development of safe and effective treatment strategies. There are many complex interactions between the immune system and prostate cancer. Although our understanding of these interactions is improving, further understanding will lead to novel treatment strategies. These include the idea that manipulation of cellular pathways, such as the work with growth factor receptors, can lead to tumor stabilization and eventually cytoreduction with continued cell turnover. The adjuvant use of immunotherapy for prostate cancer could also help increase efficacy of current oncologic treatments. This may be even more significant when used in conjuction with nomograms that may predict men who are at particularly high risk for failure of local treatment, and who would be better served with adjuvent immune therapy. The safety and efficacy of gene therapy for prostate cancer has been demonstrated through various preclinical and clinical trials, and potentially holds the greatest promise. In recent years, interest in this field has expanded and will continue to do so. Because it is conveniently administered through ultrasound-guided transrectal injection, it is also conceivable that gene therapy applied in an outpatient clinic may someday replace current therapy to treat early prostate cancer. As a therapy, it is the culmination of the work of many disciplines that will result in an elegant targeted, efficient, and versatile strategy against prostate cancer. It is conceivable that, in the near future, any of these experimental modalities will be developed to replace hormone ablation therapy which causes unpleasant side effects, decreases the quality of life of the patient, and only temporarily controls the disease. Factors that limit the disseminated use of these advanced therapies as standards of care include time, funding, and fear from the general public; however, these should diminish as the number of successful clinical trials increase.",
author = "Pratik Desai and Jim{\'e}nez, {Juan A.} and Chinghai Kao and Thomas Gardner",
year = "2006",
month = "5",
doi = "10.1016/j.ucl.2005.12.005",
language = "English",
volume = "33",
pages = "247--272",
journal = "Urologic Clinics of North America",
issn = "0094-0143",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Future Innovations in Treating Advanced Prostate Cancer

AU - Desai, Pratik

AU - Jiménez, Juan A.

AU - Kao, Chinghai

AU - Gardner, Thomas

PY - 2006/5

Y1 - 2006/5

N2 - Many novel techniques for the treatment of prostate cancer are being aggressively investigated for two reasons: (1) prostate cancer is prevalent in the population, and (2) the current treatments for advanced prostate cancer are woefully inadequate. Antiangiogenesis has great potential as stand-alone therapy to transform prostate cancer into a chronic disease or, in combination with the available therapies, to provide curative approaches with decreased treatment-related morbidities. Further understanding of the angiogenic cascade will reveal additional molecular targets and advancements in molecular delivery approaches, such as gene therapy, will lead to the development of safe and effective treatment strategies. There are many complex interactions between the immune system and prostate cancer. Although our understanding of these interactions is improving, further understanding will lead to novel treatment strategies. These include the idea that manipulation of cellular pathways, such as the work with growth factor receptors, can lead to tumor stabilization and eventually cytoreduction with continued cell turnover. The adjuvant use of immunotherapy for prostate cancer could also help increase efficacy of current oncologic treatments. This may be even more significant when used in conjuction with nomograms that may predict men who are at particularly high risk for failure of local treatment, and who would be better served with adjuvent immune therapy. The safety and efficacy of gene therapy for prostate cancer has been demonstrated through various preclinical and clinical trials, and potentially holds the greatest promise. In recent years, interest in this field has expanded and will continue to do so. Because it is conveniently administered through ultrasound-guided transrectal injection, it is also conceivable that gene therapy applied in an outpatient clinic may someday replace current therapy to treat early prostate cancer. As a therapy, it is the culmination of the work of many disciplines that will result in an elegant targeted, efficient, and versatile strategy against prostate cancer. It is conceivable that, in the near future, any of these experimental modalities will be developed to replace hormone ablation therapy which causes unpleasant side effects, decreases the quality of life of the patient, and only temporarily controls the disease. Factors that limit the disseminated use of these advanced therapies as standards of care include time, funding, and fear from the general public; however, these should diminish as the number of successful clinical trials increase.

AB - Many novel techniques for the treatment of prostate cancer are being aggressively investigated for two reasons: (1) prostate cancer is prevalent in the population, and (2) the current treatments for advanced prostate cancer are woefully inadequate. Antiangiogenesis has great potential as stand-alone therapy to transform prostate cancer into a chronic disease or, in combination with the available therapies, to provide curative approaches with decreased treatment-related morbidities. Further understanding of the angiogenic cascade will reveal additional molecular targets and advancements in molecular delivery approaches, such as gene therapy, will lead to the development of safe and effective treatment strategies. There are many complex interactions between the immune system and prostate cancer. Although our understanding of these interactions is improving, further understanding will lead to novel treatment strategies. These include the idea that manipulation of cellular pathways, such as the work with growth factor receptors, can lead to tumor stabilization and eventually cytoreduction with continued cell turnover. The adjuvant use of immunotherapy for prostate cancer could also help increase efficacy of current oncologic treatments. This may be even more significant when used in conjuction with nomograms that may predict men who are at particularly high risk for failure of local treatment, and who would be better served with adjuvent immune therapy. The safety and efficacy of gene therapy for prostate cancer has been demonstrated through various preclinical and clinical trials, and potentially holds the greatest promise. In recent years, interest in this field has expanded and will continue to do so. Because it is conveniently administered through ultrasound-guided transrectal injection, it is also conceivable that gene therapy applied in an outpatient clinic may someday replace current therapy to treat early prostate cancer. As a therapy, it is the culmination of the work of many disciplines that will result in an elegant targeted, efficient, and versatile strategy against prostate cancer. It is conceivable that, in the near future, any of these experimental modalities will be developed to replace hormone ablation therapy which causes unpleasant side effects, decreases the quality of life of the patient, and only temporarily controls the disease. Factors that limit the disseminated use of these advanced therapies as standards of care include time, funding, and fear from the general public; however, these should diminish as the number of successful clinical trials increase.

UR - http://www.scopus.com/inward/record.url?scp=33646049076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646049076&partnerID=8YFLogxK

U2 - 10.1016/j.ucl.2005.12.005

DO - 10.1016/j.ucl.2005.12.005

M3 - Article

VL - 33

SP - 247

EP - 272

JO - Urologic Clinics of North America

JF - Urologic Clinics of North America

SN - 0094-0143

IS - 2

ER -